Sep 29, 2016
ReadCoor will commercialize the Wyss Institute’s (FISSEQ) fluorescent in situ RNA sequencing technology
Posted by Karen Hurst in categories: biotech/medical, business, engineering, neuroscience
Boston-based startup completes $23 million Series A financing to leverage novel imaging platform of gene locations towards gaining diagnostic insights and delivering therapeutics for cancer, immuno-oncology, infectious diseases, neurological and neuromuscular diseases, brain function and cognitive disorders
BOSTON—(BUSINESS WIRE)—ReadCoor, Inc., today announced completion of an oversubscribed $23 million Series A financing round and its concurrent launch from Harvard University’s Wyss Institute for Biologically Inspired Engineering. ReadCoor will commercialize the Wyss Institute’s FISSEQ (fluorescent in situ sequencing) technology.